

Effectiveness in the Treatment of Changes in the Oral Mucosa of a Patient with Coronavirus

Giyazova M. M.

Bukhara State Medical Institute

ABSTRACT

To date, these studies are of great interest in terms of long-term observations and symptomatic. Infectious inflammation of the mucous membrane of the upper respiratory tract, including and pharynx, are a variety of representatives of probable infectious agents, the inability to accurately and quickly determine the spectrum of pathogens of the pathological process, the existence of about 99% of bacteria in the form of biofilms attached to the substrate, resistant to immune system factors and resistant to the action of antimicrobial drugs, inhibition of the composition of the normal microbiota and, as a consequence, a decrease in mucosal immunity, as well as the risk of developing superinfection and complications during treatment with chemical antiseptics and antibacterial drugs [5, 6].

KEYWORDS: *Coronavirus, Treatment.*

The most common complication of the disease is viral pneumonia, which can lead to acute respiratory distress syndrome and subsequent acute respiratory failure. Multiple organ failure, septic shock and venous thromboembolism are also complications of coronavirus infection. It is possible to develop long-term complications, called postcovid syndrome. Postcovid syndrome is a pathological condition of the body after a coronavirus, accompanied by a variety of symptoms that can manifest themselves constantly or in waves. More than half of the patients who have had a coronavirus infection have signs of damage to the oral cavity. The most frequent manifestations include: - ulcers, plaques, cracks, rashes on the mucous membranes of the oral cavity; - darkening or discoloration of the enamel; - inflammation, bleeding gums; - carious lesions, stomatitis; - loosening and loss of teeth; - candidiasis. Widespread lesions are weakness of the masticatory muscles and an increase in the size of the salivary glands.

For young patients, weakness of the masticatory muscles is more characteristic. In addition, lesions such as facial pain and paresthesia may occur. Some patients indicate violations of the temporomandibular joint. [1] Some of the complications that arise are associated with drug therapy used in COVID-19, in particular with antibiotic therapy, which is indicated when a bacterial infection is attached. The predominant subjective manifestations of the negative effects of antibiotics: dryness in the oral cavity, changes in taste sensitivity. The most common form of acute inflammation of the pharyngeal mucosa is viral tonsillopharyngitis. The cause of the development of catarrhal inflammation in the pharynx may be representatives of various respiratory viruses. Viral-bacterial associations are often detected (in children up to 60% of cases of upper respiratory tract infections). Acute mycotic pharyngeal lesion is extremely rare, usually against the background of significant immune disorders [5, 7, 8]. Bacterial inflammation in the pharynx is diagnosed in 30-40% of children and up to 15% of the adult population.

The development of acute bacterial inflammation in the pharynx due to the invasion of beta-hemolytic streptococcus group A requires mandatory administration of systemic antibiotics. It is

<https://cejsr.academicjournal.io>

known that against the background of systemic antimicrobial treatment, such undesirable effects as antibiotic-associated diarrhea, allergic reactions, hepato-, neuro- and ototoxic effects, negative effects on the blood system, photosensitization, negative effects on the microbiome are not uncommon [9].

In OTF of non-streptococcal etiology, the main drug direction is topical etiopathogenetic and symptomatic therapy. The advantages of this type of treatment are the targeted delivery of the active substance to the pathological focus, the absence or minimal systemic effect, reducing the risk of selection of resistant strains of microorganisms, as well as the softening, moisturizing and enveloping effect of auxiliary components. At the same time, it is necessary to take into account the absence of antiviral action in a number of topical preparations, contraindications to the use of herbal ingredients in patients with allergies, the possible presence of microbial resistance.

Ineffective therapy contributes to the persistence of pathogenic pathogens on the mucous membrane of the oropharynx and in the crypts of the tonsils, an increased risk of recurrence of acute tonsillopharyngitis, a longer and more severe course of banal respiratory diseases, an increase in the frequency and chronization of pathology of ENT organs. Based on the above, local drugs for the treatment of infectious and inflammatory diseases of the pharynx should have a wide range of effects on pathogens, including in the form of microbial communities (biofilms), do not contribute to the growth of resistance, reduce the risk of superinfection and the development of complications, quickly stop clinical symptoms and restore the quality of life, have good tolerance and high.

The factors of acquired immunity include secretory IgA and IgG and B- and T-lymphocytes. Innate immunity is represented by phagocytosis, interferons, complement system, innate lymphoid cells (NK cells, natural killers), as well as antimicrobial peptides (lysozyme, defensins, lactoferrin, properdin) [2.4.6.8]. The insufficiency of mucosal immunity is based on a decrease in the synthesis of secretory IgA, immaturity of immune processes (incomplete phagocytosis, low ability to synthesize interferons), imperfection of mucosal and skin barriers, high suppressor activity of regulatory T cells, the development of a primary immune response to most antigens with the formation of IgM without the formation of persistent memory [13].

The results of the study by other authors show that the causes of a decrease in mucosal immunity in children may be a physiological delay in the maturation (immaturity) of the immune system, a decrease in the production of interferon, IgA and lysozyme, bacterial and viral infections, unfavorable environmental conditions, irrational use of drugs, frequent stress. Unrecognized partial immunodeficiency occurs in 13-22% of clinical cases of respiratory infections in the population [19]. Lysozyme is a factor of nonspecific (innate) immunity contained in saliva, tears, breast milk, respiratory tract secretions, forming nonspecific protection [15.17].

Antiviral action is carried out by reducing the absorption of the virus and its penetration into target cells, binding to viral DNA / RNA and suppressing viral replication. Antibacterial and antifungal action is carried out by an enzymatic mechanism due to the hydrolysis of the cell wall of bacteria and fungi, in which muramylpeptide is formed – a powerful natural stimulator of immunity [17]. The antimicrobial effect is due to and the cationic mechanism during the incorporation of lysozyme into the cell membrane and the formation of pores, which increases the permeability of membranes to other antibacterial and antifungal agents. In addition, lysozyme has an anti-filmlike effect, suppressing the adhesion and growth of biofilms of *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Candida albicans* and anti-inflammatory effect, suppressing excessive activation of macrophages and neutrophils, restraining the migration of pro-inflammatory cells to the focus of inflammation and oxidative stress, binding and neutralizing extracellular inflammatory mediators [16.17].

<https://cejsr.academicjournal.io>

Lysobact ® contains in its composition as active active substances substances corresponding to those that are present in the human body. The lysozyme in the composition of the drug is similar in its action, amino acid sequence and molecular weight to the human lysozyme produced in the human body. In addition to lysozyme, the composition of the drug Lysobact ® includes pyridoxine (vitamin B6), which contributes to the repair of damaged mucosa, has an anti-aphthous effect, and also participates in the synthesis of amino acids, including cysteine, which provides antioxidant protection and limits inflammatory reactions in viral and bacterial infections [7.9.11.13].

According to the team of authors, in children with chronic adenoiditis (HA) and exudative otitis media (ESO), when using the drug Lysobact ® , there is a marked decrease in the number of pathogenic microorganisms on the nasopharyngeal mucosa compared with patients of the control group who received traditional treatment. When using the drug Lysobact ® , the growth rates of the obligate microflora of the nasopharyngeal mucosa in the main group significantly exceed those of the control group receiving traditional therapy [9].

Let's highlight the most common causes of glossitis: injury to the tongue with sharp pieces of food, a dental prosthesis; exposure to hot water and food, burns; improper and unstable oral hygiene; smoking, addiction to alcohol, poisoning with heavy metal salts; allergy to toothpaste, components of mouthwash, materials of orthopedic structures; the presence of herpes viruses in the body, staphylococci, yeast-like fungi. Glossitis can be a symptom of the presence of a common disease in the body. The most common cases of glossitis as a symptom of concomitant disease are observed in the following diseases: infectious diseases (scarlet fever, measles and others); diseases of the gastrointestinal tract; blood diseases; hypervitaminosis; oral diseases (especially stomatitis). Also, different forms of glossitis can manifest themselves differently in different conditions of the body. Thus, diamond-shaped median glossitis often accompanies chronic diseases of the gastrointestinal tract, especially a reduced degree of acidity of gastric juice.

So, in the main group, 10 days after the start of treatment, there were 3.6 times more patients with a normalized tympanogram compared to the control group. Also, in the main group, a decrease in indications for surgical treatment was revealed. No undesirable side effects were detected in any observed patient [11.13]. In the work of other researchers, it was noted that in children from 3 to 7 years old with acute respiratory pathology who received Lysobact ® , there was a significant increase in the level of secretory IgA and a decrease in the duration of catarrhal phenomena compared with the control group [11]. According to our clinic, in patients with inflammatory diseases of the pharynx, the dynamics of relief of pain, discomfort and dry cough on the 9th day after the course of treatment with Lysobact ® was twice as pronounced as in the comparison group. After 8 days. after the start of treatment, no new pathogens (superinfection) were detected in 77% of cases in the main group, and in the control group after a course of antiseptic use – only in 53% of patients. No adverse events were observed in any clinical case [40].

Conclusions

Along with the dynamics of clinical symptoms, the choice of therapy should also take into account the factor of the influence of microbiocenosis: the need for systemic antibacterial treatment is available only in a certain group of patients, and frequently used topical antimicrobial chemotherapy and antiseptics can cause a violation of the microflora, leading to a decrease in local immunity, and cause bacterial superinfection due to a violation of the microbiome. The drug Lysobact ® , providing biocenosis-sparing and reparative action, occupies one of the leading places in the arsenal of medicines for the treatment of patients with pharyngeal pathology. Lysobact ® has a wide spectrum of action, does not cause resistance and increases mucosal immunity. The drug can be taken for children from 3 years old, and the age restriction is only due to the fact that the tablets need to be absorbed.

<https://cejsr.academicjournal.io>

Lysozyme is actively used in the modern food industry, as it is a natural preservative. Due to its effectiveness in eliminating oily bacteria, it is most often used in the manufacture of cheeses, the production technology of which requires long maturation [1.3.5.7.9.11.13.15.17]. These cheeses are used in the treatment of dysbiosis in children with gastroduodenitis and intestinal dysfunctions, as well as in children with acute myeloblastic and lymphoblastic leukemia in remission. In combination with chemotherapy, lysozyme prevents a sharp decrease in the content of bifidobacteria and promotes the elimination of opportunistic intestinal microflora [14.15.17].

A decrease in the level of lysozyme, which is able to inactivate isoantigens, contributes to the development of the tumor process. In oncological diseases, the deficiency of an endogenous enzyme is determined in the blood serum during the differential diagnosis of pigmented neoplasms of the eye. In an experiment on rats with lymphosarcoma, a decrease in the level of lysozyme in peripheral blood was observed, and in most cancer patients there was a decrease in all indicators of phagocytic activity [12]. The deficiency of endogenous lysozyme, despite the multifactorial development of the oncological process, serves as one of the conditions contributing to the emergence and progression of tumor formation.

This can be explained by a surge in lysozyme activity as a response to pain irritation, and subsequently a stage of refractory producer cells and catabolism of lysozyme in the blood occur [13.14]. Diseases are associated with drug intolerance and sensitization by one or another medication. The first clinical manifestations of drug-induced stomatitis are hyperemia and swelling of the oral mucosa, then bubble rashes and erosions form. The smoothness of papillae, puffiness, "lacquer" surface, absence of plaque is noted on the tongue. The lips are covered with a white coating, tightly soldered to the tissues. For the diagnosis of the disease, the correct collection of anamnesis is necessary. In addition, glucocorticosteroid drugs are indicated in the treatment of coronavirus infection, of which dexamethasone is most often used. This drug slows down tissue regeneration, promotes the occurrence of petechiae and ecchymosis on the skin and oral mucosa, bleeding gums.

Also, glucocorticosteroid drugs can be the cause of aphthous stomatitis. Painful round ulcers (aft) are formed mainly on the inner surfaces of the cheeks, palate, tongue, which after a while become covered with a yellowish coating. Exacerbation of periodontitis in the first group of patients is caused by a coronavirus infection. COVID-19 and the ongoing therapy against it have a negative effect on the tissues of the oral mucosa. The oral cavity is being attacked by SARS-CoV-2, so this condition should be given maximum attention. Therefore, the task of dentists is to provide timely medical care not only at a therapeutic appointment, but also to carry out preventive measures that increase the local and general immunity of the patient's body.

REFERENCES

1. Шпынев К.В., Кречиков В.А. Современные подходы к диагностике стрептококкового фарингита. Клиническая микробиология и антимикробная химиотерапия. 2007;9(1):20-33. Режим доступа: <https://smacjournal.ru/publication/2007/1/smac-2007-t09-n1-p020>.
2. Поляков Д.П., Карнеева О.В., Рязанцев С.В., Гаращенко Т.И., Гуров А.В., Казанова А.В., Максимова Е.А. Острый тонзиллофарингит: клинические рекомендации. М.; 2016. 24 с. Режим доступа: http://www.nmaoru.org/files/KR306_Tonzillofaringit.pdf.
3. Тюркина С.И., Минасян В.С., Савенкова М.С., Китайгородский А.П., Овечкина Н.В., Кац Т.Г., Лапшина Т.А. Лечение и профилактика аденоидитов бактериальными лизатами у часто болеющих детей. Детские инфекции. 2013;12(1):26-30. <https://doi.org/10.22627/2072-8107-2013-12-1-26-30>.
4. Карпова Е.П., Ардатская М.Д., Захарова И.Н., Сугян Н.Г., Оборкин В.Ю. Биоценозосберегающая терапия острых воспалительных заболеваний ротоглотки у детей.

<https://cejsr.academicjournal.io>

Медицинский совет. 2017;(19):168-173. Режим доступа: <https://www.med-sovet.pro/jour/article/view/2209>.

5. Чеботарь И.В., Маянский А.Н., Кончакова Д., Лазарева А.В., Чистякова В.П. Антибиотикорезистентность биопленочных бактерий. Клиническая микробиология и антимикробная химиотерапия. 2012;14(1):51-58. Режим доступа: <https://smac-journal.ru/publication/2012/1/smac-2012-t14-n1-p051/smac-2012-t14-n1-p051.pdf>.
6. Giyazova M. M. Modern Treatment of Diseases of the Oral Mucosa and Periodontal Under the Influence of Covid 19 // International Journal on Integrated Education. Volume 4, Issue 10, Oct 2021 P. 96- 98
7. Giyazova M. M. Specificity of the course and improvement of treatment of diseases of the oral mucosa and periodontal cavity under the influence of covid 19 // International scientific and practical online conference. ACTUAL PROBLEMS PEDIATRIC DENTISTRY» 10- may 2021. P. 336
8. Giyazova M. M. Specificity of the Course and Improvement of Treatment of Diseases of the Oral Mucosa and Periodontal Cavity under the Influence of Covid 19 // International Conference on Social and Humanitarian Research 7-18th September, 2021, Poland ISBN: 978-83-956810-7-3. P. 116-117
9. Giyazova M. M. Olimov S. Sh. MODERN ORAL INFECTION IN PATIENTS WITH COVID 19 DISEASES // 2nd International Conference on Science Technology and Educational Practices Hosted from Samsun, Turkey <http://euroasiaconference.com> May 15th -16 th 2021. P. 266 – 267
10. Giyazova M. M., Olimov S. Sh. Changes in the oral cavity in patients with covid 19 diseases // Journal For Innovative Development in Pharmaceutical and Technical Science (JIDPTS) Volume:4, Issue:5, May:2021 (J I D P T S) ISSN(O):2581-693 P.79 – 81
11. Shodiya SHADIYEVA, Malika GIYAZOVA. Comorbidity of periodontal and gastrointestinal diseases // Society and innovations Journal home page: P. 424 – 425
12. Ильясов Азиз Саидмуратович, Гиязова Малика. Мухаммадовна КАЛАМУШЛАР ТЎҒРИ ИЧАГИНИНГ ЛИМФОИД ШАКЛЛАНИШИНИНГ ТУЗИЛИШИ ВА ТАРҚАЛИШИ // Биология ва тиббиёт муаммолари 2021, №4 (129) 184 – 187 б
13. И.Ш.Садиков., М.М. Гиязова., Е.К.Эронов Динамика изменение бохимических показателей крови животных при остром отравление протиофосфом // « Наука молодых» . С. 27 – 29
14. Н.К.Рузиева., М.М. Гиязова., Г.С. Ниёзова. Изучение антропометрических показателей у детей 3 – летного возраста в норме и у детей с детским церебральным параличом // Материалы XIV международной Научно – практической конференции молодых ученых 28 апреля 2016 года. С. 73 – 76
15. Шадиева Ш.Ш., Гиязова М.М. Сочетанная патология: заболевания пародонта и гастродуоденальной зоны // STOMATOLOGIYA № 2 (83) 2021. С.80 – 83
16. Giyazova M.M. Structure Of Treatment of Diseases of The Oral Mucosa and Periodontal Under the Influence of Covid 19 // Eurasian Scientific Herald. Volume 3| December, 2021. P. 37-40
17. Гиязова М.М., Саноева М.Ж. «Нейростоматологические особенности поражения структур рта при короновирусной инфекции» // Нейродегенеративные и сосудистные заболевания нервной системы. Республика научно – практическая конференция (с международным участием) С. 28 – 29